Liver Cancer (Hepatocellular Carcinoma) Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceDeficiency common in liver disease and associated with worse HCC outcomes; supports immune function
Anti-inflammatory effects; may help with cancer-related cachexia and support liver function
Supporting Stack
Additional supplements for enhanced resultsMay have antiproliferative effects in HCC; deficiency common in liver disease
Supporting Studies (1)
Hepatoprotective effects; antioxidant; may reduce treatment side effects
Supporting Studies (1)
Anti-cancer properties in preclinical studies; may inhibit HCC proliferation
Support liver function; reduce muscle loss in cirrhosis; may improve outcomes after treatment
Supporting Studies (1)
Deficiency common in liver disease; supports immune function and liver metabolism
Supporting Studies (1)
Antioxidant; deficiency associated with increased liver cancer risk in endemic areas
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, usually arising in the setting of chronic liver disease. Major risk factors include hepatitis B or C infection, cirrhosis from any cause (alcohol, fatty liver disease), aflatoxin exposure, and certain metabolic conditions. HCC is often diagnosed late because the diseased liver may not show symptoms until cancer is advanced. Treatment depends on stage and liver function and may include surgery, transplant, ablation, chemoembolization, or systemic therapy.
CRITICAL: Liver cancer requires comprehensive oncological management. Treatment decisions depend on tumor stage, liver function (Child-Pugh score), and performance status. Options include surgical resection, liver transplantation (for appropriate candidates), ablation, transarterial chemoembolization (TACE), radioembolization, or systemic therapies (sorafenib, lenvatinib, immunotherapy). These supplements may provide supportive benefit but DO NOT treat cancer. Always discuss supplements with your oncology team as some may interact with treatments. Addressing underlying liver disease (viral hepatitis, alcohol) is crucial.
* Vitamin D deficiency is very common in liver disease (the liver converts vitamin D to its active form). Low vitamin D levels are associated with worse HCC outcomes. Supplementation supports immune function and may be beneficial.
* Omega-3 Fatty Acids have anti-inflammatory effects and may help with cancer-related weight loss (cachexia). They also support liver function.
* Vitamin K has shown potential antiproliferative effects against HCC in some studies, particularly vitamin K2 (menatetrenone). Deficiency is common in liver disease due to impaired absorption and storage.
* Milk Thistle (Silymarin) has hepatoprotective and antioxidant properties. It may help protect remaining liver function and reduce treatment side effects.
* Curcumin has shown anti-cancer effects against HCC in laboratory studies, including inhibiting cell proliferation and inducing apoptosis.
* Branched-Chain Amino Acids (BCAAs) are often depleted in cirrhosis. Supplementation can help maintain muscle mass, improve nutritional status, and may improve outcomes after HCC treatment.
* Zinc deficiency is very common in chronic liver disease and contributes to complications. Supplementation supports liver function and immune health.
* Selenium deficiency has been associated with increased liver cancer risk, particularly in areas with endemic low selenium levels.
Expected timeline: Nutritional support is ongoing throughout treatment. Discuss any supplements with your oncologist before starting.
Clinical Perspective
Hepatocellular carcinoma (HCC): primary liver cancer, usually in cirrhotic liver. Etiologies: HBV, HCV, alcoholic cirrhosis, NAFLD/NASH, aflatoxin, hemochromatosis, PBC/PSC. Surveillance: ultrasound +/- AFP every 6 months in at-risk patients. Staging: BCLC system (very early/early/intermediate/advanced/terminal) guides treatment. Child-Pugh score for liver function. Alpha-fetoprotein: tumor marker (elevated in ~50%).
CRITICAL: Treatment by stage - Very early/early (BCLC 0-A): resection, transplant (Milan criteria), ablation. Intermediate (BCLC B): TACE. Advanced (BCLC C): systemic therapy - first-line atezolizumab + bevacizumab or sorafenib/lenvatinib. Terminal (BCLC D): best supportive care. Transplant curative for appropriate candidates. Treat underlying disease (antivirals for HBV/HCV). Supplements are SUPPORTIVE CARE only - discuss with oncology team for interactions.
* Vitamin D (B-grade): Often deficient in liver disease; VDR in hepatocytes. Meta-analysis: deficiency associated with worse prognosis (PMID: 27498401). Systematic review: importance in liver cancer (PMID: 28371132). 2000-4000 IU daily; monitor 25(OH)D.
* Omega-3 Fatty Acids (C-grade): Anti-inflammatory; anti-cachexia. Review: preclinical evidence, limited clinical data (PMID: 24965308). 2-3g EPA+DHA daily.
* Vitamin K (B-grade): MK-4 (menatetrenone) studied for HCC. Meta-analysis: may reduce recurrence (PMID: 22552152). 45mg MK-4 daily in studies (high dose). Coagulation: vitamin K deficiency in liver disease but supplementation beyond deficiency correction less clear.
* Milk Thistle (C-grade): Silymarin - hepatoprotective, antioxidant. Review: potential in HCC (PMID: 23796755). 420-600mg silymarin daily. Limited clinical evidence.
* Curcumin (C-grade): Multiple anti-cancer mechanisms in vitro. Review: HCC mechanisms (PMID: 25535206). Clinical trials limited. 500-1000mg enhanced-absorption daily. Check for drug interactions.
* BCAAs (B-grade): Muscle maintenance in cirrhosis. Meta-analysis: improved outcomes in HCC (PMID: 25266054). 5-12g BCAAs daily. Especially post-treatment.
* Zinc (C-grade): Deficiency common in cirrhosis. Systematic review: importance in liver disease (PMID: 24815593). 25-50mg daily.
* Selenium (C-grade): Antioxidant selenoproteins. Review: deficiency and liver cancer risk (PMID: 15537682). 100-200mcg daily.
Biomarker targets: AFP, liver function tests, Child-Pugh score, imaging (CT/MRI for treatment response), nutritional parameters, vitamin D level.
Protocol notes: Surveillance crucial - HCC often asymptomatic until advanced. At-risk patients: US +/- AFP every 6 months. Antiviral therapy: HBV suppression reduces HCC risk; HCV cure reduces but doesn't eliminate risk (continue surveillance). Alcohol cessation. Weight management for NAFLD. Nutrition important - cirrhosis is catabolic; adequate protein, BCAAs. Hepatic encephalopathy: limit protein only if precipitated by dietary excess. Avoid hepatotoxins. Vaccinations (hepatitis A/B if not immune). Drug interactions: many supplements affect CYP enzymes - discuss with oncology. Milk thistle may interact with some chemotherapies. Green tea extract in high doses can be hepatotoxic. Avoid immune-stimulating supplements during immunotherapy without discussion. Palliative care integration important. Portal hypertension management. Watch for complications: ascites, variceal bleeding, SBP. Psychological support. Clinical trials.